Compare Public Storage (PSA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Vertex Pharmaceuticals Incorporated — how do they compare? Public Storage trades at $286.07 (market cap $53.35B), while Vertex Pharmaceuticals Incorporated trades at $508.42 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× Public Storage's market cap, and Public Storage pays a 4.2% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Storage for 130 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PSA | VRTX | |
|---|---|---|
Market Cap | $53.35B | $127.55B |
Volume | 1,176,034 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $330.47 | $557.96 |
52-Week Low | $258.44 | $407.37 |
Typical Hold Time | 130 Days | 120 Days |
Enterprise Value | $67.62B | $121.68B |
Dividend Yield | 4.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $286.07, up 1.45% with recent earnings beats and strong profitability metrics including 41.8% net income margin. Technical indicators show bearish momentum with support at $277, while fundamentals reveal stable revenue growth and a $3.00 dividend. The company recently completed its Public Storage Canada acquisition and issued C$400 million in senior notes.
The stock presents a mixed outlook with analyst consensus target of $328.33 offering 15% upside, though technical weakness and valuation premiums pose risks. Key opportunities include operational momentum and reliable yield, while headwinds include oversupply concerns and interest rate sensitivity.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
